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Livingston G1, Katona C2, Roch B3
1University College London, London, United Kingdom; 2University of
Kent at Canterbury, Kent, United Kingdom; 3H. Lundbeck A/S, Paris,
France
A study by Kurz et al. (2003) proposed categorisation of burden
of illness in Alzheimer’s Disease (AD) dividing activities of daily
living into basic and instrumental categories. OBJECTIVE: To
validate the approach used by Kurz et al. METHODS: We
analysed patient data from the LASER (London and South East
Region) UK Alzheimer Project of 224 AD patients using the
above methodology. We transformed activity of daily living item
scores from the ADCS-ADL scale into qualitative evaluations of
level of dependency. Six items corresponding to basic activities
were identiﬁed (eating, walking, bowel/ bladder function,
bathing, grooming, dressing). The remaining 17 items were
explored using principal component analysis. Backward selec-
tion on ANOVA models was used to determine the most rele-
vant cost drivers. RESULTS: Two factors corresponding to
domestic and communication activities had eigenvalues >1.
Patients were then classiﬁed into three disability clusters by
applying nearest centroid-sorting method to different standard-
ized (mean = 0; SD = 1) ADL sub-scores. The ﬁrst cluster had
low scores on basic, domestic and communication ADL and was
designated as “dependent”. The second had high scores on basic
and relatively high scores on both domestic and communication
ADL and was designated as “non-dependent”. The third had
high scores on basic ADL but only moderate impairment in
domestic and communication ADL (designated “Non-
Dependent with Instrumental Functional Disability; ND-IFD”).
Clinical scale scores differed signiﬁcantly between disability
levels. Estimated costs over 6 months also differed signiﬁcantly
(3013€ for non-dependent patients, 8788€ for ND-IFD and
21,649€ for dependent patients). Disability was a signiﬁcant pre-
dictor of costs in the more advanced stages of the disease whereas
severity of cognitive impairment was a stronger predictor in the
earlier stages. CONCLUSION: This study validates the three AD
categories and conﬁrms the relevance of disability as a cost
driver.
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EVALUATION OF GENERIC DISPENSING INCENTIVE
PROGRAM (GDIP)
Hong SH
University of Arkansas for Medical Sciences, Little Rock, AR, USA
OBJECTIVES: An insurer has implemented the Generic Dis-
pensing Incentive Program (GDIP) through a pharmacy beneﬁt
manager (PBM) in a local market beginning the second half of
2001 to encourage network pharmacy providers to dispense pre-
scriptions with generic drugs. The GDIP increases reimburse-
ment amount by $2.00 for any prescription dispensed with a
generic drug when network pharmacies have recorded generic
dispensing rate of 41% to 46%, and increases it by $4.00 when
generic dispensing rate is 46% or higher. This study evaluates
the impact the GDIP has on generic dispensing rate. METHODS:
The PBM provided pharmacy data consisting of numbers of pre-
scriptions ﬁlled with brand-name and generic drugs, and their
respective drug ingredient costs for each network pharmacy for
seven 6-month periods (1st half of 2000–1st half of 2003). The
program cost was computed as the additional reimburse amount.
The program saving was as “the increase in the number of
generic dispensing” multiplied by ingredient cost difference
between brands and generic drugs. An important assumption
was that the increased generic dispensing was only attributed to
the GDIP. RESULTS: The GDIP cost $2.4 million but saved
around $5.4 million for the network pharmacies (668–676 phar-
macies). The generic dispensing rate hovered around 38% before
the GDIP but continually increased to 44.26% in the latest
period. The number of pharmacies that had moved upward in
generic dispensing rate increased while the number of pharma-
cies with downward transitions decreased. There were six times
more upward transitions than downward ones in the lasted
period. CONCLUSIONS: The GDIP increased the generic dis-
pensing rate by 6%. That increase in generic dispensing rate was
translated into the net savings of $3 million into the ﬁrst half of
2003.
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EFFECT OF COPAY INCREASE ON FOUR MEASURES OF
COMPLIANCE: A NATURAL EXPERIMENT
Meissner B, Shinogle J, Kozma C, Shah M, Franklin M
University of South Carolina, Columbia, SC, USA
OBJECTIVES: Compliance is a behavior that responds to incen-
tives. Economic theory would suggest that as the price of a
product increases, the quantity demanded decreases. Therefore
compliance would be altered but the magnitude of the behav-
ioral effect is not known. This descriptive study examines the
effect of a prescription copayment change on four measures of
compliance behavior, medication possession ratio (MPR), con-
sistence, number of gaps, and maximum gap within one thera-
peutic category STATINs. METHODS: The data for this study
is from a for proﬁt network model managed care organization.
On January 1, 1999, the co-payment for prescription drugs
